Lupin Limited, a prominent global pharmaceutical company, has announced that its Research and Development facility at the Lupin Research Park in Pune has achieved the prestigious LEED Platinum Certification for Operations and Maintenance from the U.S. Green Building Council (USGBC). This certification, one of the highest standards in green building performance, underscores Lupin’s commitment to … Read more
The development of ammonia-powered engines has taken a significant step forward with the commencement of full-scale testing of a two-stroke engine running on ammonia at MAN Energy Solutions’ Research Centre Copenhagen (RCC). This marks a major milestone in the push towards cleaner and sustainable maritime propulsion technologies. Key Details:- After more than a year of … Read more
Regenerative medicine is indeed a transformative frontier in healthcare, with its potential to address previously untreatable conditions and improve quality of life. The Ajinomoto Group’s focus on AminoScience highlights the vast potential of amino acids in innovative healthcare solutions. By leveraging their unique biochemical properties, Ajinomoto has positioned itself at the forefront of developing … Read more
Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill). Latanoprost is commonly used to treat elevated intraocular pressure (IOP) in individuals with open-angle glaucoma or ocular hypertension. This approval allows the company to manufacture and market the generic version … Read more
Targeting molecules involved in the establishment maintenance, and reactivation of the latent HIV reservoir is indeed a promising strategy for curing HIV. Understanding and interrupting the mechanisms of latency and immune evasion are key to overcoming the challenges posed by the reservoir. Here’s an overview of the most promising approaches and their potential: 1. Latency-Reversing … Read more
Proud to announce the launch of Toripalimab in India, the first and only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab is a New Biological Entity (NBE). The combination of Toripalimab … Read more
Potential first and only DHE autoinjector for tough-to-treat migraines and cluster headaches Exenatide approval highlights Amneal’s capabilities in developing GLP-1 injectables BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and … Read more
Orchid Pharma Limited, (‘Orchid Pharma’) based in Chennai, India, the only Indian pharmaceutical company to have ever invented a New Chemical Entity (NCE), announced the launch of its new drug – Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. In a … Read more
Indoco Remedies Ltd. announced the final approval of the Company’s Abbreviated NewDrug Application (ANDA) for Varenicline Tablets, 0.5 mg and 1 mg, to market a generic equivalent to the reference listed drug (RLD), Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF) from USFDA.Varenicline Tablets, 0.5 mg and 1 mg bioequivalent and … Read more
SeQuent Scientific and Viyash Lifesciences Announce Strategic Merger to Create a Global AnimalHealth Leader with End-to-End Integrated Capabilities The proposed merger is expected to create a unique & differentiated platform with leadingmarket position in Animal healthcare and integrated capabilities for global pharmaceuticalclients, supported by a strong operating backbone Combined entity to have access to … Read more
